AAUM (Average Assets Under Management) of ₹94,875.28 Cr for Apr-Jun 2026 is the combined figure across Direct and Regular plans — sourced from AMFI India's quarterly disclosure. Equity Holdings above shows only the stock portion from the latest portfolio filing.
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Banks | 15.6% | 15.8% | ▲ +0.2% |
| Pharmaceuticals & Biotechnology | 11.4% | 11.0% | ▼ -0.3% |
| Auto Components | 9.2% | 9.7% | ▲ +0.5% |
| IT - Software | 6.3% | 7.1% | ▲ +0.8% |
| Insurance | 5.8% | 5.7% | ● 0.0% |
| Industrial Products | 6.5% | 5.7% | ▼ -0.8% |
| Retailing | 3.7% | 3.5% | ▼ -0.2% |
| Healthcare Services | 3.5% | 3.3% | ▼ -0.1% |
| Finance | 2.6% | 3.0% | ▲ +0.3% |
| Personal Products | 2.9% | 2.9% | ● +0.0% |
| Sector | Prev | Curr ▼ | Delta |
|---|---|---|---|
| Banks | 15.8% | 15.9% | ▲ +0.1% |
| Pharmaceuticals & Biotechnology | 11.0% | 11.7% | ▲ +0.7% |
| Auto Components | 9.7% | 9.6% | ▼ -0.1% |
| IT - Software | 7.1% | 7.4% | ▲ +0.3% |
| Insurance | 5.7% | 5.7% | ● +0.0% |
| Industrial Products | 5.7% | 5.3% | ▼ -0.4% |
| Retailing | 3.5% | 3.6% | ● +0.1% |
| Healthcare Services | 3.3% | 3.5% | ▲ +0.2% |
| Consumer Durables | 2.9% | 2.9% | ● +0.1% |
| Finance | 3.0% | 2.8% | ▼ -0.2% |
Comparing Jul 2026 → Aug 2026
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Aster DM Healthcare Limited ₹907.39 Cr |
Healthcare Services | 0.42% | 0.84% | +0.42% |
| 2 | Coforge Limited ₹3,101.16 Cr |
IT - Software | 2.56% | 2.86% | +0.30% |
| 3 | IPCA Laboratories Limited ₹3,575.69 Cr |
Pharmaceuticals & Biotechnology | 3.01% | 3.30% | +0.29% |
| 4 | Glenmark Pharmaceuticals Limited ₹3,325.23 Cr |
Pharmaceuticals & Biotechnology | 2.85% | 3.07% | +0.22% |
| 5 | Bosch Limited ₹1,561.22 Cr |
Auto Components | 1.22% | 1.44% | +0.22% |
| 6 | PB Fintech Limited ₹1,834.56 Cr |
Financial Technology (Fintech) | 1.49% | 1.69% | +0.20% |
| 7 | Havells India Limited ₹977.31 Cr |
Consumer Durables | 0.70% | 0.90% | +0.20% |
| 8 | Gland Pharma Limited ₹1,751.05 Cr |
Pharmaceuticals & Biotechnology | 1.44% | 1.62% | +0.18% |
| 9 | Petronet LNG Limited ₹390.54 Cr |
Gas | 0.20% | 0.36% | +0.16% |
| 10 | Indian Bank ₹3,312.30 Cr |
Banks | 2.93% | 3.06% | +0.13% |
| # | Stock | Sector | Jul 2026 | Aug 2026 | Change |
|---|---|---|---|---|---|
| 1 | Balkrishna Industries Limited ₹3,268.66 Cr |
Auto Components | 3.37% | 3.02% | -0.35% |
| 2 | Cummins India Limited ₹2,079.84 Cr |
Industrial Products | 2.19% | 1.92% | -0.27% |
| 3 | Fortis Healthcare Limited ₹2,911.32 Cr |
Healthcare Services | 2.91% | 2.69% | -0.22% |
| 4 | Marico Limited ₹2,481.89 Cr |
Agricultural Food & other Products | 2.51% | 2.29% | -0.22% |
| 5 | Hindustan Petroleum Corporation Limited ₹2,225.10 Cr |
Petroleum Products | 2.26% | 2.05% | -0.21% |
| 6 | Emami Limited ₹109.00 Cr |
Personal Products | 0.28% | 0.10% | -0.18% |
| 7 | The Federal Bank Limited ₹4,559.52 Cr |
Banks | 4.36% | 4.21% | -0.15% |
| 8 | Mahindra & Mahindra Financial Services Limited ₹2,466.21 Cr |
Finance | 2.43% | 2.28% | -0.15% |
| 9 | AIA Engineering Limited ₹1,444.67 Cr |
Industrial Products | 1.48% | 1.33% | -0.15% |
| 10 | Alkem Laboratories Limited ₹1,746.44 Cr |
Pharmaceuticals & Biotechnology | 1.73% | 1.61% | -0.12% |
79 stocks — Aug 2026
| # | Stock | Sector | Cap | Weight & Value |
|---|---|---|---|---|
| 1 |
₹4,559.52 Cr |
Banks |
4.21%
|
|
| 2 |
₹4,316.27 Cr |
Banks |
3.98%
|
|
| 3 |
₹4,108.03 Cr |
Insurance |
3.79%
|
|
| 4 |
₹3,575.69 Cr |
Pharmaceuticals & Biotechnology |
3.30%
|
|
| 5 |
₹3,325.23 Cr |
Pharmaceuticals & Biotechnology |
3.07%
|
|
| 6 |
₹3,312.30 Cr |
Banks |
3.06%
|
|
| 7 |
₹3,268.66 Cr |
Auto Components |
3.02%
|
|
| 8 |
₹3,101.16 Cr |
IT - Software |
2.86%
|
|
| 9 |
₹2,911.32 Cr |
Healthcare Services |
2.69%
|
|
| 10 |
₹2,502.19 Cr |
Retailing |
2.31%
|
Disclaimer: Data sourced from individual AMC monthly portfolio disclosures, as mandated by SEBI/AMFI. While we strive for accuracy, errors in parsing or presentation may occasionally occur. This is not investment advice. Please consult a SEBI-registered investment adviser before making any investment decisions.
Found a discrepancy or have feedback? Contact Us — we read every message personally.